Reiko Nishihara, PhD; Paul Lochhead, MB, ChB; Aya Kuchiba, PhD; et al.
free access
JAMA. 2013;309(24):2563-2571. doi:10.1001/jama.2013.6599
Nishihara and coauthors examined data from the National Nurses’ Health Study and the Health Professionals Follow-up Study, which involved 127 865 individuals for approximately 3.2 million person-years, to determine whether the association of aspirin intake with colorectal cancer risk differs according to status of tumor BRAF oncogene mutation. In an editorial, Pasche elaborates on their findings.
ONLINE FIRST
Karen E. Joynt, MD, MPH; Atul A. Gawande, MD, MPH; E. John Orav, PhD; et al.
free access
JAMA. 2013;309(24):2572-2578. doi:10.1001/jama.2013.7103
Joynt and coauthors measured the proportion of acute care hospital and emergency department costs deemed preventable among high-cost patients in a sample of 1 114 469 Medicare beneficiaries aged 65 years or older. Carroll and Frakt provide comment in an editorial.
ONLINE FIRST
Sandra L. Decker, PhD; Deliana Kostova, PhD; Genevieve M. Kenney, PhD; et al.
free access
JAMA. 2013;309(24):2579-2586. doi:10.1001/jama.2013.7106
To document the health care needs and health risks of uninsured low-income adults who could gain Medicaid coverage under the Affordable Care Act, Decker and coauthors analyzed and compared health conditions among uninsured lowincome adults and adults enrolled in Medicaid. Carroll and Frakt provide comment in the related Editorial.
Bruce L. Jacobs, MD, MPH; Yun Zhang, PhD; Florian R. Schroeck, MD, MS; et al.
free access
has multimedia
has audio
JAMA. 2013;309(24):2587-2595. doi:10.1001/jama.2013.6882
Using SEER-Medicare data for men diagnosed with prostate cancer between 2004 and 2009, Jacobs and coauthors investigate the use of advanced treatment technologies (ie, intensity-modulated radiotherapy and robotic prostatectomy), as opposed to prior standards (ie, traditional external beam radiation treatment and open radical prostatectomy) and observation.
-
Audio Author Interview:
Use of Advanced Treatment Technologies Among Men at Low Risk of Dying From Prostate Cancer